Published On: 12/4/2024
The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at The Liver Meeting 2024 titled, “Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status.”
This study explores the stability of the NASH-CHECK patient-reported outcome measure in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Using data from the TARGET-NASH cohort, we investigate the reliability and consistency of the NASH-CHECK scores over time, even in patients with stable disease. Watch the video presentation by Dr. Sanyal.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
McKinley Peter
Digital Marketing Specialist
+1 (352) 514-8045
More News
-
05/09/2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research -
05/08/2025
EASL 2025 Research: Presentation by Michael Roden, MD -
04/25/2025
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis? -
04/03/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data -
03/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life